direkt zum Inhalt springen

direkt zum Hauptnavigationsmenü

Sie sind hier

TU Berlin

Inhalt des Dokuments

Publications Fechner 1996-2009


  • Pinkert S., Westermann D., Wang X., Klingel K., Dörner A., Savvatis K., Grössl T., Krohn S., Tschöpe C., Zeichhardt H., Kotsch K., Weitmann K., Hoffmann W., Schultheiss H.-P., Spiller O.B., Poller W., Fechner H. (2009). Prevention of cardiac dysfunction in acute coxsackievirus B3 cardiomyopathy by inducible expression of a soluble coxsackievirus-adenovirus receptor. Circulation. 120:2358-2366.
  • Bhonde, M.R., Hanski, M.L., Stehr, J., Jebautzke, B., Peiró-Jordán, R., Fechner, H., Yokoyama, K.K., Lin, W.C., Zeitz, M.M., Hanski, C. (2009). Mismatch repair system decreases cell survival by stabilizing the tetraploid G1 arrest in response to SN-38. Int J Cancer. [Epub ahead of print]
  • Fecker, L.F., Schmude, M., Jost, S., Hossini, A.M., Picó Hurtado, A., Wang, X., Schwarz, C., Fechner, H., Eberle, J. (2009). Efficient and selective tumor cell lysis and induction of apoptosis in melanoma cells by a conditional replication-competent CD95L adenovirus. Exp Dermatol. Sep 2. [Epub ahead of print]
  • Werk, D., Pinkert, S., Heim, A., Zeichhardt, H., Grunert, H.-P., Poller, W., Erdmann, V.A., Fechner, H., Kurreck, J. (2009). Combination of soluble coxsackievirus-adenovirus receptor and anti-coxsackievirus siRNAs exerts synergistic antiviral activity against coxsackievirus B3. Antiviral Res; 83:298-306.
  • Suckau, L., Fechner, H., Chemaly, E., Krohn, S., Hadri, L., Kockskämper, J., Westermann, D., Bisping, E., Ly, H., Wang, X., Kawase, Y., Chen, J., Liang, L., Sipo, I., Vetter, R., Weger, S., Kurreck, J., Erdmann, V., Tschope, C., Pieske, B., Lebeche, D., Schultheiss, H.-P., Hajjar, R.J., Poller, W.C. (2009). Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy. Circulation; 119:1241-1252.


  • Rothe, D., Werk, D., Dutkiewicz, M., Schubert, S., Grunert, H.-P., Zeichhardt, H., Erdmann, V.A., Fechner, H., Kurreck, J. (2008). Inhibition of picornaviruses by means of RNA interference. Nucleic Acids Symp Ser (Oxf).;(52):63-64.
  • Fechner, H., Sipo, I., Westermann, D., Pinkert, S., Wang, X., Suckau, L., Kurreck, J., Zeichhardt, H., Muller, O.J., Vetter, R., Tschope, C., Poller, W. (2008) Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy. J Mol Med; 86:987-97.
  • Skurk C., Wittchen F., Suckau L., Witt H., Noutsias M., Fechner H., Schultheiss H.-P., Poller W. (2008) Description of a local cardiac adiponectin system and its deregulation in dilated cardiomyopathy. Eur Heart J ;29:1168-80.


  • Eberle, J., Fecker, L., Hossini, A., Kurbanov, B.M., Fechner, H. (2008) Apoptosis pathways: Promising targets to overcome therapy resistance of malignant melanoma. Exp Dermatol ; 17: 1-11 Sipo, I., Fechner, H., Pinkert, S., Suckau, L., Wang, X., Weger, S., Poller, W. (2007) Differential internalization and nuclear uncoating of self-complementary AAV pseudotype vectors as determinants of cardiac cell transduction. Gene Ther, 14, 1319-29

  • Fechner, H., Pinkert, S., Wang, X., Sipo, I., Suckau, L., Sollerbant, K., Zeichhardt, H.,Grunert, H.-P., Schultheiss, H.-P., Poller, W. (2007) Coxsackievirus B3 and adenovirus infections of cardiac cells are efficiently inhibited by vector-mediated RNA interference targeting their common receptor. Gene Ther. 14, 960-71.
  • Oppermann, M., Fechner, H., Geilen, C.C., Eberle, J. (2007) Dimethylsulfoxide (DMSO) enhances the doxycycline-dependentprotein expression in Tet-On melanoma cells and thus increases the effect of proapoptotic genes. Biotechniques,42:304, 306
  • Fechner, H., Wang, X., Hurtado Picó, A., Wildner, J., Suckau, L. Pinkert, S., Sipo, I. Weger, S. Poller, W. (2007) A bidirectional Tet-dependent promotor construct regulating the expression of E1A for tight control of oncolytic adenovirus replication. J. Biotechnol. 127:560-74
  • Wittchen, F., Suckau, L., Witt, H., Skurk, C., Lamers, J., Fechner, H., Ungethüm, U., Tschöpe, C., Rauch, U., Ruiz, P., Kühl, U., Schultheiss, H.-P. Poller, W. (2007) Genomic expression profiling of human inflammatory cardiomyopathy (DCMi) suggests novel therapeutic targets J Mol Med. 85:253-267

  • Fechner, H., Suckau, L., Kurreck, J., Sipo, I., Wang, X., Pinkert, S., Loschen, S., Rekittke, J., Weger, S., Dekkers, D., Vetter, R., Erdmann, V.A., Schultheiss, H.-P., Paul, M., Lamers, J., Poller, W. (2007) Highly efficient and specific modulation of cardiac active calcium sequestration by adenovector-based expression of a short hairpin RNA targeting phospholamban. Gene Ther. 14:211-208.


  • Dorner, A., Grunert,H.P.Chandrashekharan, K., Fechner, H., Knowlton K.U., Ssik, A. Pauschinger, M. Zeichhardt, H. Schultheiss, H.P. (2006) Treatment of coxsackievirus-B3-infected BALB/c mice with the soluble coxsackie adenovirus receptor CAR4/7 aggravates cardiac injury J Mol Med. 84:842-851.
  • Sutter A.P., Fechner H. (2006) Gene therapy for gastric cancer: is it promising?. World J Gastroenterol. 12: 380-387. Sipo I., Hurtado Picó A., Wang X., Eberle J., Petersen I., Weger S., Poller W., Fechner H. (2006) An improved Tet-On regulatable FasL-adenovirus vector system for lung cancer therapy. J Mol Med. 84:215-225.
  • Poller W, Fechner H, Kuhl U, Pauschinger M, Schultheiss HP (2006). New therapeutics targets in chronic viral cardiomyopathy. Ernst.Schering.Res Found.Workshop 287-303.


  • Sipo I., Wang X., Hurtado Picó A., Suckau L., Weger S., Poller W., Fechner H (2005).Gene Ther. 13:173-186.

Tamoxifen-regulated adenoviral E1A chimeras for the control of tumor selective oncolytic adenovirus replication in vitro and in vivo.

  • Hurtado Picó, A., Wang, X., Sipo, I., Siemetzki, U., Eberle J., Poller, W., Fechner H. (2005). Viral and nonviral factors causing unspecific replication of tumor- and tissue-specific promotor-dependent oncolytic adenoviruses. Mol Ther. 11, 563-577.
  • Fecker, L.F., Geilen, C.C., Hossini, A.M., Schwarz, C., Fechner, H., Bartlett, D.L., Orfanos, C.E., Eberle, J. (2005). Selective induction of apoptosis in melanoma cells by tyrosinase promoter-controlled CD95 ligand overexpression. J Invest Dermatol. 124, 121-128.


  • Poller W., Fechner H., Kurreck J., Pauschinger M., Kuhl U., Erdmann V.A., Lamers J.M., Schultheiss H.P. (2004). Nucleic acid-based modulation of cardiac gene expression for the treatment of cardiac diseases. Approaches and perspectives. Z Kardiol, 93, 171-93.


  • Fechner, H., Wang, X., Srour, M.A., Siemetzki,U., Seltmann, H., Sutter A.P., Scherübl, H., Zouboulis, C.C., Schwaab, R., Hillen, W., Schultheiss, H.-P. and Poller, W. (2003). A tetracycline-dependent transactivator-transrepressorsystem for tight external control of adenovirus replication and therapeutic transgene expression. Gene Ther. 10, 1680-1690.
  • Srour, M.A., Fechner, H., Wang, X., Siemetzki, U., Albert, T., Oldenburg, J., Poller, W., Brackmann H.-H., Schwaab, R. (2003). Regulation of expression of human factor IX using an adenovirus-mediated doxycycline-inducable gene expression system. Thromb. and Haemostasis. 90,398-05.
  • Fechner, H., Noutsias, M., Hinze, K., Wang, X., Escher, F., Dekkers, D., Lamers, J.M.J., Vetter, R., Paul, M., Schultheiss, H.-P., Tschoepe, C., and Poller, W. (2003). Regulation of Coxsackie-adenovirus-receptor expression during myocardial tissue formation and repair. Circulation 107, 876-82.
  • Fechner H., Johnston P.E., Sharp, N.J., Montague, P., Griffiths, I.R. , Wang, X, Olby, N., Looman, A.C., Poller, W., and Flegel, T (2003). Molecular genetic and expression analysis of a-tocopherol transfer protein mRNA in German Shepherd dogs with degenerative myelopathy. Berl. Munch. Tierarztl. Wochenschr. 116, 31-36.


  • Poller W, Fechner H., Noutsias M., Tschoepe C., Schultheiss HP. (2002). Highly variable expression of virus receptors in the human cardiovascular system. Implications for cardiotropic viral infections and gene therapy. Z Kardiol. 91, 978-91.
  • Lamers, J.M.J., Eizema, K., Fechner, H., Schneider-Rasp, S., Wang, H., and Poller, W.C. (2002).Cardiovascular Remodeling and Heart Failure, 87-101 Sarcoplasmatic reticulum proteins as potential targets for gene therapy of heart failure.


  • Noutsias, M, Fechner, H, de Jonge, H, Wang, X, Dekkers, D, Houtsmuller, AB, Pauschinger, M, Bergelson, J, Warraich, R, Yacoub, M, Hetzer, R, Lamers, J, Schultheiss, HP, and Poller, W (2001).Circulation. 104, 275-280.

Human Coxsackie-adenovirus-receptor is colocalized with integrins alpha(v)beta(3) and alpha(v)beta(5) on the cardiomyocyte sarcolemma and upregulated in dilated cardiomyopathy: implications for cardiotropic viral infections.


  • Fechner, H, Wang, X, Wang, H, Jansen, A, Pauschinger, M, Scherubl, H, Bergelson, JM, Schultheiss, HP, and Poller, W (2000). Trans-complementation of vector replication versus coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells. Gene Ther. 7, 1954-1968.
  • Eizema, K, Fechner, H, Bezstarosti, K, Schneider-Rasp, S, van der Laarse, A, Wang, H, Schultheiss, HP, Poller, WC, and Lamers, JMJ (2000). Adenovirus-based phospholamban antisense expression as a novel approach to improve cardiac contractile dysfunction: comparison of a constitutive viral versus an endothelin-1-responsive cardiac promoter. Circulation. 101, 2193-2199.
  • Lamers, J.M.J., Bezstarosti, K., Eizema, K., Fechner, H., Schultheiss, H.P., and Poller, W.C. (2000).European Journal of Heart Failure 2, 42.Proteins of the sarcoplasmic reticulum as potential targets for gene therapy of heart failure,
  • Lamers, J.M.J., Bezstarosti, K., Eizema, K., Fechner, H., Schneider-Rasp, S., Wang, H., Dekkers, D., de Jonge, H.W., Schoemarker, R.G., van Veghel, R., Houtsmuller, A.B., van der Laarse, A., and Poller, W.C. (2000). Proteins of sarcoplasmatic reticulum as potential targets for gene therapy of heart failure. Toraxcentre J. 12, 16-23.
  • Witt, W., Kolleck, I., Fechner, H., Sinha, P., and Rustow, B. (2000). Regulation by vitamin E of the scavenger receptor BI in rat liver and HepG2 cells. J.Lipid Res. 41, 2009-2016.
  • Blankenstein, P., Bondzio, A., Fechner, H., Beier, D., Marquardt, O., Looman, A.C., and Ebner, D.A nucleotide deletion causing a translational stop in the protease reading frame of bovine leukaemia virus (BLV) results in modified protein expression and loss of infectivity. (2000). J.Vet.Med.B.Infect.Dis.Vet.Public Health. 47, 361-371.


  • Fechner, H., Haack, A., Wang, H., Wang, X., Eizema, K., Pauschinger, M., Schoemaker, R., Veghel, R., Houtsmuller, A., Schultheiss, H.P., Lamers, J., and Poller, W. (1999). Expression of Coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. Gene Ther. 6, 1520-1535.
  • Kolleck, I., Schlame, M., Fechner, H., Looman, A.C., Wissel, H., and Rustow, B. (1999). HDL is the major source of vitamin E for type II pneumocytes. Free Radic.Biol.Med. 27, 882-890.
  • Poller, W., Merklein, F., Schneider-Rasp, S., Haack, A., Fechner, H., Wang, H., Anagnostopoulos, I., and Weidinger, S. (1999). Molecular characterisation of the defective alpha 1-antitrypsin alleles PI Mwurzburg (Pro369Ser), Mheerlen (Pro369Leu), and Q0lisbon (Thr68Ile). Eur.J.Hum.Genet. 7, 321-331.


  • Fechner, H., Schlame, M., Guthmann, F., Stevens, P.A., and Rustow, B. (1998). alpha- and delta-tocopherol induce expression of hepatic alpha- tocopherol-transfer-protein mRNA. Biochem.J. 331, 577-581.
  • Guthmann, F., Hohoff, C., Fechner, H., Humbert, P., Borchers, T., Spener, F., and Rustow, B. (1998). Expression of fatty-acid-binding proteins in cells involved in lung-specific lipid metabolism. Eur.J.Biochem. 253, 430-436.
  • Beier, D., Blankenstein, P., and Fechner, H. (1998). Possibilities and limitations for use of the polymerase chain reaction (PCR) in the diagnosis of bovine leukemia virus (BLV) infection in cattle. Dtsch.Tierarztl.Wochenschr. 105, 408-412.
  • Blankenstein, P., Fechner, H., Looman, A.C., Beier, D., Marquardt, O., and Ebner, D. (1998).Berl.Munch.Tierarztl.Wochenschr. 111, 180-186.

Polymerase chain reaction (PCR) for detection of BLV provirus - a practical complement for BLV diagnosis?.


  • Fechner, H., Blankenstein, P., Looman, A.C., Elwert, J., Geue, L., Albrecht, C., Kurg, A., Beier, D., Marquardt, O., and Ebner, D. (1997). Provirus variants of the bovine leukemia virus and their relation to the serological status of naturally infected cattle. Virology 237, 261-269.


  • Fechner, H. Kurg, A., Blankenstein, P., Mewes, G., Geue, L., Albrecht, C., and Ebner, D. (1996).Berl.Munch.Tierarztl.Wochenschr. 109, 446-450.

Direct use of cell lysates in PCR-based diagnosis of bovine leukemia virus infection.

  • Fechner, H., Kurg, A., Geue, L., Blankenstein, P., Mewes, G., Ebner, D., and Beier, D. (1996).Zentralbl.Veterinarmed.[B.] 43, 621-630.

Evaluation of polymerase chain reaction (PCR) application in diagnosis of bovine leukaemia virus (BLV) infection in naturally infected cattle.

nichtbegutachtete Veröffentlichungen

Fechner, H, Kurreck, J. (2008). Vector-mediated and viral delivery of short hairpin RNAs RSC Biomolecular Sciences, Therapeutic Nucleotides ed. J. Kurreck, Chapter 13, S. 267-295. Royal Society of Chemistry, Cambridge, UK

Poller, W, Suckau, L, Pinkert, S, Fechner, H. (2008) RNA Interference and microRNA Modulation for treatment of cardiac disorders. RNA Technologies in Cardiovascular Medicine and Research, eds. V.A. Erdmann W Poller, J. Barciszewski., DOI: 10.1007/978-3-540-78709-9; Springer-Verlag, Berlin, Heidelberg, Germany

Zusatzinformationen / Extras


Schnellnavigation zur Seite über Nummerneingabe